Effects of glucose-lowering agents on ischemic stroke

Area of Science:

• Cardiology
• Endocrinology
• Neurology

Background:

• Diabetes mellitus (DM) is a significant risk factor for cardiovascular events, particularly ischemic stroke.
• Ischemic stroke in diabetic patients is often more severe, leading to poorer outcomes.
• Conventional strict glycemic control has not demonstrated a reduction in ischemic stroke risk.

Purpose of the Study:

• To evaluate the impact of newer glucose-lowering agents on cardiovascular events and ischemic stroke risk in patients with diabetes.
• To explore the mechanisms behind the cardiovascular benefits of specific antidiabetic medications.
• To compare the efficacy and safety profiles of various diabetes treatments concerning stroke prevention.

Main Methods:

• Review of recent randomized, placebo-controlled trials investigating glucose-lowering agents.
• Analysis of data on cardiovascular outcomes, including ischemic stroke, associated with specific drug classes.
• Assessment of the influence of factors like body weight and blood pressure on treatment efficacy.

Main Results:

• Glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors have shown reductions in cardiovascular events.
• Semaglutide specifically demonstrated a reduced risk of ischemic stroke, independent of glucose-lowering effects.
• Pioglitazone reduced recurrent stroke risk in specific patient groups but has safety concerns; sulfonylureas and DPP-4 inhibitors showed neutral cardiovascular effects.

Conclusions:

• Newer diabetes agents like GLP-1 RAs and SGLT-2 inhibitors offer cardiovascular protection beyond glycemic control.
• These agents may reduce ischemic stroke risk through beneficial effects on weight and blood pressure.
• Certain diabetes medications are more suitable than others for managing cardiovascular risk in high-risk diabetic populations.